A clinical trial is investigating the use of inhaled Fexlamose for treating adult participants aged 40 to 80 with moderate to severe COPD. The study focuses on individuals with a verified diagnosis of cigarette smoking-related COPD and specific spirometry performance criteria.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.